 Aptevo Therapeutics Inc. Nasdaq: APVO, a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM bispecific technology platform, and Alligator Bioscience AB Nasdaq Stockholm: ATORX, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announced that new preclinical data for ALG.APV-527 are being presented at the PEGS Virtual Interactive Global Summit, on June 10, 2020 in an oral presentation entitled, ALG.APV-527: Tumor-directed T-cell stimulation, in vivo tumor regression, and safety studies of a 4-1BB x 5T4 ADAPTIRTM bispecific antibody. 